Findings 13 patients were interviewed (n=9 in two focus groups, n=4 1:1 interviews) (54% male, 62% white British). Themes, sub-themes and illustrative quotes are provided in figure 1. The two over-arching themes were: The Recovery Journey and The Rehabilitation Boat. Patients experienced varied journeys through recovery, but described a feeling of together-ness and support in the rehabilitation environment.

Overall, the severity of acute and post-COVID-19 symptoms were unexpected. For some, symptoms were misunderstood or misbelieved. Expectations for rehabilitation were varied. The opportunity to reflect on shared experiences was valuable and facilitated by offering education sessions as an open forum which was perceived as an important part of the programme. There was a sense of being a survivor and gratitude for support in recovery. Patients described a shift in values to prioritising a healthy lifestyle.

Conclusions Attending rehabilitation for COVID-19 was considered acceptable and important part of recovery and a positive experience. The opportunity to share the experience with others in the same boat was highly valued in the context of an unexpected and potentially lonely COVID-19 recovery.

REFERENCES


Assessing, managing and predicting outcomes in ILD

P144 RED CELL DISTRIBUTION WIDTH (RDW) AND NEUTROPHIL LYMPHOCYTE RATIO (NLR) AS PROGNOSTIC MARKERS IN IDIOPATHIC PULMONARY FIBROSIS (IPF)

1 R Shuttleworth, 2 T Nancarrow, 3 RL Wolterton, 4 M White, 5 S Lines, 6 J Mandizha, 7 A Duckworth, 8 AM Russell, 9 MA Gibbons, 10 CJ Scotton. 1 Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; 2 University of Exeter, Exeter, UK; 3 Royal Cornwall Hospitals Trust, Truro, UK

10.1136/thorax-2021-BTSabstracts.253

Introduction and Objectives Idiopathic Pulmonary Fibrosis (IPF) has a median survival of ~ 2–3 years, but there is significant variability and hence difficulty in advising patients at a personal level. The full blood count (FBC) is readily accessible and gives a Red Cell Distribution Width (RDW), which
describes the percentage variation in red cell size. The neutrophil and lymphocyte count can be used to calculate a ratio (NLR). Limited published work has evaluated the prognostic significance of these markers in IPF. Our aim was to assess longitudinal changes in RDW and NLR as potential prognosticators in IPF.

Methods Patients with IPF were identified from the Royal Devon and Exeter Hospital (2005–2019). Data collected: baseline characteristics, survival, PFTs and FBC <6 months from diagnosis and 6–18 months during follow-up. Patients with insufficient data were excluded. Blood parameters were stratified into quartiles for subsequent Kaplan-Meier survival analyses, Mann-Whitney U-test and Spearman’s rank correlation.

Results 131 patients were included in analysis. Median change/month for NLR (deltaNLR) and RDW (deltaRDW) were 0.17 and 0.02 respectively, indicating minimal longitudinal variation. Anti-fibrotic treatment did not modify deltaRDW or deltaNLR. However, stratifying by median deltaRDW significantly impacted on survival (median 33 months with deltaRDW>0.02 vs 59 months; P = 0.04). Median survival based on baseline RDW was 35 months (highest quartile) vs 47 months (1st–3rd quartiles) although this did not reach significance (P = 0.1439). Median survival based on follow-up RDW was 25 months (highest quartile) vs 59 months (1st–3rd quartiles; P = 0.0021) and this was negatively correlated with FVC (r = 0.405). Both baseline and follow-up NLR had significantly shorter median survival in the highest quartile (28 months; p < 0.05) compared with 47 months (baseline 1st–3rd quartile) or 59 months (follow-up 1st–3rd quartile). FVC was negatively correlated to baseline NLR (P = 0.0282).

Conclusions RDW and NLR demonstrated significant relationships with survival and correlations with FVC. Increasing RDW resulted in poorer outcomes. Although limited by the small retrospective cohort, this data indicates that readily available FBC may have utility in prognostication and progression monitoring in IPF, independent of antifibrotic treatment. RDW may be confounded by co-morbidities; further work to assess this is warranted.

Abstract P145 Figure 1  Survival according to decline in lung function at one year

## Poster sessions

1. **P145** MARGINAL SHORT TERM LUNG FUNCTION CHANGES PREDICT MORTALITY IN PATIENTS WITH FIBROTIC HYPERSENSITIVITY PNEUMONITIS

1. C. Macaluso, 2. C. Boccabella, 3. M. Kokosi, 4. Kouranos, 5. PM. George, 5.5. G. Margaritopoulos, 1. PI. Molyneaux, 6. F. Chua, 4.7. M. Maher, 4.6. GR. Jenkins, 6. Desai, 8. A. Devaj, 1. AU. Wells, 1.6. EA. Renzoni, 1.7. CW. Stock. 1. Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 1.2. IRCA/IRCCS, L’Mandic’ Hospital Merate (LC) – Department of Pneumology, Merate, Italy; 3. Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario ‘A. Gemelli’ – IRCCS, University of the Sacred Heart, Rome, Italy; 4. Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK; 5. ILD Unit, London North West University Hospital Healthcare Trust, London, UK; 6. Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK; 7. Hastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA; 8. Department of Radiology, Royal Brompton and Harefield Clinical Group, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

**Background and Objective** A proportion of patients with fibrotic hypersensitivity pneumonitis (fHP) follow a progressive disease course despite immunosuppressive treatment. Little is known about predictors of mortality in fHP. We aimed to investigate the impact of marginal, short-term lung function changes in fHP on mortality.

**Methods** Baseline demographics were recorded for 145 consecutive patients with a Multi-Disciplinary Team diagnosis of fHP, as well as baseline and one year follow-up lung function, baseline echocardiographic findings, bronchoalveolar lavage (BAL) cellularity, and all-cause mortality. Marginal changes in FVC ≥5% and DLCO ≥10% at one year were calculated. Cox proportional hazards analysis was performed to test for associations with mortality.

**Results** Baseline lung function severity (FVC, DLCO, and composite physiological index (CPI)), age, and PASP ≥40mm Hg on echocardiogram were associated with early mortality, while BAL lymphocytosis was associated with improved survival. A marginal decline at one year in FVC ≥5% (HR: 3.10, 95% CI: 2.00–4.81, p < 0.001) and DLCO ≥10% (HR: 2.80 (95% CI: 1.78–4.42), p < 0.001) were associated with markedly